Study funded by NIHR Health Technology Assessment ref: 13/17/04

Slides:



Advertisements
Similar presentations
Meeting need and improving coverage workshop. Meeting need: calculating and improving coverage.
Advertisements

Implementing NICE guidance
A Pilot Study of Satisfaction and Adherence with Antipsychotic Medication Amongst Prisoners Dr Alice Mills Mr Dan Bressington Dr Richard Gray Professor.
Alcohol screening and brief intervention delivery to an Irish cohort of opiate dependent methadone maintained patients. Catherine Darker (PhD) Department.
MDM Harm Reduction (needle exchange) program in Kabul-Afghanistan.
Hepatitis C prevention among people who inject drugs: reducing transmission in PWID by scaling up HCV treatment, OST and needle exchange services Matt.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.
Addiction UNIT 4: PSYA4 Content The Psychology of Addictive Behaviour Models of Addictive Behaviour  Biological, cognitive and.
Sex work among people who inject drugs in England, Wales & Northern Ireland: Findings from a National Survey of Health Harms and Behaviours Sara Croxford,
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
Prison Based Motivational Intervention Therapy for Problem Drinkers; Impact of feasibility study in HMP Altcourse Emma Pennington Research Associate CAIS.
Cocaine Services IN AN IDEAL WORLD – HOW SHOULD THEY WORK?
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1.
Needs Assessment: Young People’s Drug and Alcohol Services in Edinburgh City EADP Children, Young People and Families Network Event 7 th March 2012 Joanne.
Effects of an HIV/AIDS peer prevention intervention on sexual and injecting risk behaviors among injecting drug users (IDUs) and their risk partners in.
All Change! Infections, injecting drug use and harm reduction. Vivian Hope IDU Team, HIV & STI Department, Health Protection Services – Colindale Dr Vivian.
Drug Use and Hepatitis C Are we mindful of the gaps? Dave Liddell, SDF.
Sue Irving. Remit  To develop and recommend a set of appropriate and adequate integrated approaches for working with substance misusers, i.e. problematic.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.
1 NTA More treatment, better treatment, fairer treatment National injecting conference Annette Dale-Perera Director of Quality.
Organizing Drug Users for Public Health Policy Changes 17 th International Conference on the Reduction of Drug Related Harm Jason Farrell, Executive Director.
South West Hepatitis C Needs Assessment Dr Maya Gobin Health Protection Services (South West)
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Hepatitis C and Sexual & Reproductive Health Graham Mackintosh, Training & Capacity Officer Lesley Bon, Patient Involvement Officer.
Thematic Priorities for ATF Applications Presentation by Secretariat of Council for the AIDS Trust Fund in Briefing Session on 27 July
Why don’t Key Populations Access HIV
Deadly trio: mental health – HIV - drugs
The PROTECT study; a feasibility trial of a psychosocial intervention to reduce blood borne virus (BBV) risk A three country collaboration led by the.
IAS Satellite Session 25th July 2017 Daniel Were, PhD
1University of Kentucky, Lexington, Kentucky
Fabienne Hariga Senior Adviser, HIV/AIDS Section
The epidemiology of IPED users attending IEP services in Scotland
Effective HIV & SRH Responses Among Sex Workers and other Key Populations Module 1: National Data.
6% of adults had used one or more illicit drugs in last 12 months.
Key recommendations Successful components of physical activity interventions fall into three categories: Planning and developing physical activity initiatives.
Promoting male partner and couples testing through secondary distribution of self-tests by pregnant and postpartum women: a randomized trial Kawango Agot1,
The DEPression in Visual Impairment Trial:
Enhanced Pharmacy Provision in Edinburgh:
Kristen Williams, Jonathan J.K. Stoltman, and Mark K. Greenwald
Dr Marcello Bertotti Senior Research Fellow
Qualitative Research Results Conclusions
Cascade of care for persons newly diagnosed
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
Table 1: NHBS HET3 Participant Characteristics
Believed discrimination occurred because of their:
Integrating Hepatitis C Treatment in Primary Care
Integrating Hepatitis C Treatment in Primary Care
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Reitox National Focal Point National Bureau for Drug Prevention
Hepatitis B and C management pathways in prison:
CAIS Ltd, in association with IMSCaR, Bangor University
PrEP introduction for Adolescent Girls and Young Women
The Health Literacy National Demonstration Site – What did we do
Helping drug dependent parents and their children: Is Behavioural Couples Therapy a realistic option? Research Team Principal Investigator: Dr Anne Whittaker,
22 November 2018 Factors predicting usage of low dead space syringes and association with Hepatitis C prevalence amongst people who inject drugs in the.
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
1 Source Heor, 2 University of Bristol, 3 Bristol Drugs Project, UK
STIs among people who use drugs
ENDING THE EPIDEMICS: A FOCUS ON PEOPLE WHO INJECT DRUGS
Blood borne viral hepatitis action in Wales
Integrating Hepatitis C care for at-risk groups: Findings from a Multi-centre Observational Study in Primary and Community Care Nic An Riogh E1, Swan D¹,
Professor Jack Lambert
Information Pack Advice Leading to Public Health Advancement
The Comprehensive Model for Personalised Care
Human Dignity and Harm Reduction
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Study funded by NIHR Health Technology Assessment ref: 13/17/04 Improving injecting skills and preventing blood borne virus infection in people who inject drugs in the UK: A feasibility randomised control trial of a psychosocial intervention (PROTECT) Gail Gilchrist Gail.Gilchrist@kcl.ac.uk Study funded by NIHR Health Technology Assessment ref: 13/17/04

Declarations No conflicts of interest Study funded by NIHR Health Technology Assessment ref: 13/17/04

The Research Team King’s College London: Gail Gilchrist, Davina Swan, John Strang University of the West of Scotland: April Shaw, Alison Munro, Avril Taylor University of York: Ada Keding, Steve Parrott, Judith Watson Betsi Cadwaladr University Hospital Trust: Sarah Towers Public Health Wales: Noel Craine University of Huddersfield: Elizabeth Hughes

Recent outbreak of HIV among PWID in the UK Background In the UK, 23%-61% of people who inject drugs (PWID) are hepatitis C (HCV) positive, the rates of HIV and hepatitis B (HBV) are much lower, 0%-1.4% for HIV and 6-18% for HBV (Hahné et al., 2013; PHE, 2015) Recent outbreak of HIV among PWID in the UK Increased risk of infection for those who inject amphetamines and amphetamine-type drugs, such as, mephedrone (Hope et al., 2016) 4

Background Opiate substitution therapy and needle exchanges have reduced HIV and HCV among PWID (Degenhardt et al., 2010; Turner et al., 2011; Aspinall et al., 2014; MacArthur et al., 2014) Public Health England’s, “Shooting Up” report highlighted that in 2014 in England, Wales and Northern Ireland, sharing of needles in the previous month was reported by 17% of individuals attending drug treatment services, in Scotland this figure was 14% in 2013-2014. Addressing risks and increasing knowledge to reduce BBV among PWID remains a public health priority Alongside harm reduction provision, Psychosocial interventions (such as brief interventions, motivational interviewing, cognitive behavioural therapy and contingency management) could further decrease BBVs (Degenhardt et al., 2010) by educating PWID about transmission risks and developing strategies to avoid them. 5

Aims of the PROTECT study to understand current influences on PWID BBV risk behaviours to develop an evidence-based psychosocial intervention aimed at reducing BBV transmission risk behaviours and increasing BBV transmission knowledge among PWID to explore the feasibility of recruiting PWID to a trial comparing the intervention to control to explore the feasibility and acceptability of delivering a psychosocial intervention to PWID 6

Aims of the PROTECT study to understand current influences on PWID BBV risk behaviours to develop an evidence-based psychosocial intervention aimed at reducing BBV transmission risk behaviours and increasing BBV transmission knowledge among PWID to explore the feasibility of recruiting PWID to a trial comparing the intervention to control to explore the feasibility and acceptability of delivering a psychosocial intervention to PWID 7

The PROTECT Intervention (evidence based and informed)

How the intervention was developed Building on evidence of “what works” – review and adaptation of existing interventions [Gilchrist et al., 2017 AIDS & Behavior] Focus on what is important to PWID from our indepth interviews: Interplay of structural, situational and individual factors influenced injecting risk behaviours Focus for PWID not on BBV rather on avoiding abscesses, finding a vein etc Interventions should target other injecting-related priorities including improving injecting techniques and venous care to promote the use of sterile injecting equipment, and protective strategies to avoid risk 9

How the intervention was developed Current thinking – addressing “symbiotic ” goals for PWID, such as avoiding injecting related scars or marks and maintaining venous access, may result in the use of sterile injecting equipment (Harris & Rhodes, 2012) Inclusion of protective practices and strategies to avoid injecting risk situations such as withdrawal and lack of preparedness (Harris et al., 2012; McGowan et al., 2013; Mateu-Gelabert et al., 2014; Treolar et al., 2015).   Co-development with experts (service providers, service users, peer educators, researchers, policy makers) 10

The PROTECT intervention (3 x 1 hr sessions) Improving injecting techniques, good vein care 2 Session 2 Planning for risk situations 3 Session 3 Understanding BBV transmission risks Sessions used videos, games and exercises to facilitate discussion and build skills and strategies to reduce and avoid risk. All sessions also included a short didactic education section. Separate groups were held for women and men.

Download the PROTECT intervention https://www. kcl. ac Download the PROTECT intervention https://www.kcl.ac.uk/ioppn/depts/addictions/research/drugs/PROTECT-download-page-form.aspx or email Gail.Gilchrist@kcl.ac.uk

The feasibility trial

Recruitment Researcher recruited; posters/flyers; staff facilitated recruitment in London, York, Glasgow and North Wales PWID (not just PEDs) in past month, ≥ 18 years from community substance use and harm reduction services, and needle exchange programmes; able to speak English 14

Assessment Demographic data Injecting and sexual risk behaviours and self-efficacy Withdrawal Prevention Tactics scale tactics to avoid withdrawal episodes: saved a bag for the next morning; put aside additional drugs; stored methadone; or put aside money for getting the next bag in an emergency (Vazan et al., 2012). A fifth item asked about use of other substances, such as painkillers, to avoid withdrawal symptoms until they are able to obtain their drug of choice. BBV transmission knowledge Motivation to change behaviour Health-related Quality of Life (HRQoL) (Rabin & Charro, 2001) Health and social resource used

Intervention groups trial After baseline assessment, randomised to: Treatment group PROTECT 3 x 1 hr sessions of psychosocial intervention plus Hep C Info booklet & leaflet about HIV outbreak Control group Hep C Info booklet & leaflet about HIV outbreak only Both groups also received treatment as usual 16

Contingency management £10 for attendance at each of the 3 PROTECT intervention sessions + “Bonus” £10 if attended all 3 sessions Participants in each treatment arm received £10 for research interview/ and participants in treatment arm received £10 for participating in focus group Cash (London) versus Voucher (all other areas)

Settings and facilitators London Co-facilitated by drugs worker & peer educator (gender matched) Recruited from 2 drug treatment services/ NEX, and one homeless hostel with prescribing clinic Delivered in one drug treatment service/ travel reimbursed York Groups due to be facilitated by male BBV nurse for male group and female drug worker Due to be delivered in a drug treatment service 18

Settings and facilitators Glasgow Men’s group co-facilitated by 1 female service coordinator/1 male group worker (no female group took place) Recruited from 1 drug treatment services/ NEX Delivered in one drug treatment service North Wales Groups co-facilitated by 1 x male & 1 x female harm reduction worker Recruited from drug treatment service, homeless drop in centre and needle exchange & mobile harm reduction van Delivered at homeless drop-in/ travel reimbursed 19

Baseline characteristics   Male Female Intervention N=34 Control N=30 N=18 N=17 Age Mean (SD) 41.7 (6.81) 41.4 (7.30) 35.8 (6.06) 37.9 (8.79) Median 42.5 42 35 37 Min, Max 26, 57 22, 54 26, 48 26, 62 Number of years injecting 21.4 (8.00) 19.5 (9.01) 11.9 (7.58) 16.1 (12.14) 22 19 11.5 14 3, 36 1, 42 0, 34 0, 44 Used needle exchange in the last month 31 (91.2%) 26 (86.7%) 16 (88.9%) 16 (94.1%) Homeless 15 (44.1%) 14 (46.7%) 8 (44.4%) 5 (29.4%) HIV Positive 1 (2.9%) 0 (0.0%) Hepatitis C Positive 17 (50%) 15 (50%) 5 (27.8%) 6 (35.3%)

Feasibility 56% (99/176) of eligible participants were randomised into the feasibility trial during January and February 2016; 52 randomised to intervention and 47 to control group [34 men and 18 women] 38% (20/52) PWID attended at least one session [18 attended one session, 15 attended two sessions and 15 attended three sessions] Men were more likely to attend at least one intervention session than women (44% versus 28%). Attendance to at least one intervention session was highest in London (63%) and North Wales (54%), whereas only 25% attended in Glasgow, and no participants attended in York.

Results Those who did not attend any sessions (n=32) were more likely to be homeless (56% vs 25%, p=0.044), have injected on a greater number of days in the last month (median 25 vs 6.5, p=0.019) and used a greater number of needles from a Needle Exchange in the last month (median 31 vs 20, p=0.056). Glasgow and York had higher levels of homelessness (68% and 52% respectively) compared to London (27%) and North Wales (29%). In addition, participants injected for a greater number of days and used more needles from a Needle Exchange

Follow-up 42% (22/52) of PWID in intervention group and 49% (23/47) of PWID in control group were followed-up one month post intervention Follow-up was also highest in London (83%) and North Wales (63%), and significantly lower in Glasgow (55%) and York (43%) Follow-up was associated with fewer days of injecting in the last month (median 14 vs 27, p=0.030) and fewer injections of cocaine (13% vs 30%, p=0.063)

Feasibility trial outcomes Improved (fewer) injecting risk practices, improved self-efficacy, better hepatitis C and hepatitis B transmission knowledge and greater use of withdrawal prevention techniques in the intervention arm. At one month post-intervention amongst participants who had attended at least one session of the intervention: no increase in self-reported injecting in more “risky” sites (e.g. groin, neck) trend towards injecting on fewer days in the past 28 days Intervention does not appear to encourage riskier injecting practices or increase frequency of injecting

Acceptability to staff and participants Separate focus groups with facilitators and participants Evaluation sheets following each session completed by facilitators and participants

Possible explanations for site differences participants in some areas more complex needs (homeless, more frequent injectors etc) peer-educators co-facilitated the intervention in the London site only reimbursement for travel costs (London and North Wales), time and contingency management were paid in cash in the London site versus high street vouchers at the other three sites

Implications Complex needs of many PWID may have limited engagement of those potentially most at risk of engaging in BBV transmission behaviours women, homeless, more frequent injectors least likely to attend some participants were in prison, hospital or residential rehabilitation and therefore did not attend sessions and were not followed-up Alternative intervention delivery modes/ local solutions/ flexibility in delivery required to ensure greater reach Need for a greater embedding of BBV risk reduction in the work of substance use services/ needle exchanges

Conclusions Intervention was acceptable to both facilitators and attending participants and 57% of eligible participants agreed to be randomised, suggesting support for addressing BBV risk behaviours among PWID Considerable difficulties recruiting particular groups of PWID, mainly women and new injectors. additional barriers for women secondary distribution for new injectors PROTECT intervention has potential to positively influence some PWID BBV risk behaviour, non-attendance at the York site substantially influenced the results

Download the PROTECT intervention https://www. kcl. ac Download the PROTECT intervention https://www.kcl.ac.uk/ioppn/depts/addictions/research/drugs/PROTECT-download-page-form.aspx or email Gail.Gilchrist@kcl.ac.uk